Malin Corporation plc (MLC) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Malin Corporation plc, together with its subsidiaries, operates as an investment company in Europe and North America. It engages in the investment in life sciences and healthcare companies targeting various therapeutic areas, including oncology, immunology, and genetic diseases.
Total Revenue Chart for Malin Corporation plc
Malin Corporation plc (MLC) revenue for FY2024 was EUR 0.00. Malin Corporation plc's revenue grew from EUR 22.9M in 2015 to EUR 0.00 in 2024 (-100.0% over 9 years). Earnings per share moved from EUR -1.51 in 2015 to EUR 0.82 in 2021.
Total Revenue (Euros)
R&D as % of Revenue
Key Stats
- Market Cap
- €30.28M
- Implied Share Price
- €7.00
- Enterprise Value
- -€31.82M
- Revenue (TTM)
- €41.00M
- EBITDA
- -€2.40M
- Profit Margin
- 0.00%
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- Price/Book (MRQ)
- 0.16
- Price/Sales (TTM)
- 6.18
- EV/EBITDA
- 186.08
- EV/Revenue
- 6.08
- Dividend Yield
- —
- Book Value
- €8.90
- Free Cash Flow (FY2024)
- -€1.30M
- Free Cash Flow Yield
- -4.29%
Snapshot as of 15th August 2026 — not point-in-time controlled, may lag the live market by a few days.